

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 October 2018 (11.10.2018)



(10) International Publication Number
WO 2018/187331 A8

(51) International Patent Classification:

C07D 493/22 (2006.01) *A61K 31/357* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2018/025887

(22) International Filing Date:

03 April 2018 (03.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/482,030	05 April 2017 (05.04.2017)	US
62/526,677	29 June 2017 (29.06.2017)	US
15/814,105	15 November 2017 (15.11.2017)	US
62/586,416	15 November 2017 (15.11.2017)	US

(71) Applicants: **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). **EISAI R&D MANAGEMENT**

CO., LTD. [JP/JP]; 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 112-8088 (JP).

(72) Inventors: **KISHI, Yoshito**; 75 Cambridge Parkway, Unit E902, Cambridge, MA 02142-1233 (US). **KIRA, Kazunobu**; C/o Eisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3 Tokodai, Ibaraki, Tsukuba-shi, 300-2635 (JP). **ITO, Ken**; C/o Eisai Co., Ltd., Tsukuba Research Laboratories, 5-1-3 Tokodai, Ibaraki, Tsukuba-shi, 300-2635 (JP).

(74) Agent: **BAKER, C., Hunter**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: MACROCYCLIC COMPOUND AND USES THEREOF





Figure 1



Compound (1)

(57) Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof. Compound (1)

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

06 December 2018 (06.12.2018)

(15) Information about Correction:

see Notice of 06 December 2018 (06.12.2018)